# Meningococcal B Vaccine Recommendations by Age and Risk Factor

## Meningococcal Serogroup B Vaccines

- **Bexsero (MenB-4C, GlaxoSmithKline)**
- **Trumenba (MenB-FHbp, Pfizer)**

The two brands of MenB vaccines are not interchangeable. The series, and booster doses when indicated, must be started and completed with the same brand of vaccine.1

## Recommendations for Meningococcal Serogroup B Vaccination (Shared Clinical Decision-Making) for People Who Are Not in a Risk Group

<table>
<thead>
<tr>
<th>WHOM TO VACCINATE</th>
<th>VACCINATION SCHEDULE</th>
</tr>
</thead>
</table>
| Teens and young adults ages 16 through 23 years based on shared clinical decision-making (those who want to be vaccinated based on the risk and benefits of the vaccine). The preferred age for vaccination is 16 through 18 years. | Administer either
- **Bexsero**: Give 2 doses, 4 weeks apart, or
- **Trumenba**: Give 2 doses 6 months apart. If dose #2 is administered earlier than 6 months after dose #1, give a third dose at least 4 months after dose #2. |

## Risk-based Recommendations for Persons with Underlying Medical Conditions or Other Risk Factors

<table>
<thead>
<tr>
<th>WHOM TO VACCINATE</th>
<th>PRIMARY SERIES SCHEDULE</th>
<th>BOOSTER DOSE SCHEDULE</th>
</tr>
</thead>
</table>
| For people ages 10 years or older with
  - persistent complement component deficiencies, or complement inhibitor use2
  - anatomic or functional asplenia, including sickle cell disease
  - prolonged increased risk for exposure (e.g., microbiologists routinely working with *Neisseria meningitidis*) | Administer either
- **Bexsero**: Give 2 doses, 4 weeks apart; or
- **Trumenba**: Give 3 doses on a 0-, 1–2-, and 6-month schedule | If risk continues:
- Give first booster dose 1 year after completion of primary series.
- Give a booster dose every 2–3 years following 1st booster as long as risk continues. |

<table>
<thead>
<tr>
<th>WHOM TO VACCINATE</th>
<th>PRIMARY SERIES SCHEDULE</th>
<th>BOOSTER DOSE SCHEDULE</th>
</tr>
</thead>
</table>
| For people ages 10 years or older who are identified as at risk by public health officials during an outbreak of meningococcal serogroup B disease | Administer either
- **Bexsero**: Give 2 doses, 4 weeks apart; or
- **Trumenba**: Give 3 doses on a 0-, 1–2-, and 6-month schedule | Give a booster dose to any person identified as at risk who has completed a primary series at least 1 year earlier. Note that public health officials may recommend that a booster dose be given as early as 6 months after completion of the primary series.3 |

1. The brands of MenB vaccine are not interchangeable. If the brand of MenB vaccine used for the primary series is unknown or unavailable, complete a new primary series with the available brand.

2. Persistent complement component deficiencies include inherited or chronic deficiencies in C3, C5–C9, properdin, factor D, and factor H, or taking eculizumab (Soliris) or ravulizumab (Ultomiris).

3. In an outbreak, do not delay vaccination if brand of primary vaccine series is unknown. Counsel recipient to verify primary series brand after vaccination. If it is different or unknown, the patient should return in 4 weeks for a booster dose of the original brand or to complete the new primary series for optimal protection.